# reload+after+2024-01-19 22:47:05.870671
address1§188 East Blaine Street
address2§Suite 400
city§Seattle
state§WA
zip§98102
country§United States
phone§206 701 7914
website§https://www.sana.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
fullTimeEmployees§418
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Steven D. Harr M.D.', 'age': 53, 'title': 'President, CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1037895, 'exercisedValue': 0, 'unexercisedValue': 1032253}, {'maxAge': 1, 'name': 'Dr. Richard C. Mulligan Ph.D.', 'age': 68, 'title': 'Executive Vice Chairman & Head of Innovation Research', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bernard J. Cassidy J.D.', 'age': 68, 'title': 'Executive VP, General Counsel & Corporate Secretary', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 491388, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Nathan  Hardy M.B.A.', 'age': 47, 'title': 'Executive VP & CFO', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 683493, 'exercisedValue': 0, 'unexercisedValue': 761978}, {'maxAge': 1, 'name': 'Dr. Edward  Rebar Ph.D.', 'age': 55, 'title': 'Senior VP & CTO', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Robin  Andrulevich', 'age': 57, 'title': 'Executive VP & Chief People Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul  Brunetta M.D.', 'title': 'Senior VP and Head of Clinical & Translational Science', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christian  Hordo M.B.A.', 'age': 40, 'title': 'Executive VP & Chief Business Officer', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 485027, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sonja  Schrepfer M.D., Ph.D.', 'age': 48, 'title': 'Senior VP & Head of Hypoimmune Platform', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Terry  Fry M.D.', 'age': 56, 'title': 'Senior VP & Head of T Cell Therapeutics', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§6
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.216
currency§USD
dateShortInterest§1702598400
forwardEps§-1.08
exchange§NMS
quoteType§EQUITY
shortName§Sana Biotechnology, Inc.
longName§Sana Biotechnology, Inc.
firstTradeDateEpochUtc§1612449000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9276f67e-d58b-3beb-ac90-eb00f5f6392e
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.0
targetLowPrice§5.0
targetMeanPrice§8.8
targetMedianPrice§8.0
recommendationMean§2.1
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§4.03
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
